CLYM

Climb Bio Inc

Apr 08 • 04:00PM ET

7.10

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Apr 08, 7:05 AMClimb Bio completes dosing in healthy-volunteer trial of subcutaneous budoprutug formulation

Peers: VRTX CRSP BMRN ALNY IONS RARE EXEL NBIX RNA EDIT

| Held by: VTI VXF IWC DFAS DFMC DFAU AVSC DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.89	Insider Own	12.22%	Shs Outstand	47.77M	Perf Week	3.65%
Market Cap	339.15M	Forward P/E	-	EPS next Y	-1.36	Insider Trans	3.03%	Shs Float	41.93M	Perf Month	-2.07%
Enterprise Value	238.61M	PEG	-	EPS next Q	-0.29	Inst Own	73.89%	Short Float	4.30%	Perf Quarter	86.35%
Income	-59.85M	P/S	-	EPS this Y	-28.17%	Inst Trans	9.90%	Short Ratio	3.00	Perf Half Y	292.27%
Sales	0.00M	P/B	2.11	EPS next Y	-20.76%	ROA	-31.10%	Short Interest	1.80M	Perf YTD	77.50%
Book/sh	3.36	P/C	3.36	EPS next 5Y	-29.17%	ROE	-32.15%	52W High	8.04 -11.69%	Perf Year	528.32%
Cash/sh	2.12	P/FCF	-	EPS past 3/5Y	19.93% -0.24%	ROIC	-37.23%	52W Low	1.07 563.55%	Perf 3Y	136.67%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.98% 8.97%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	58.37%	Oper. Margin	-	ATR (14)	0.57	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.16	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	56.30	Recom	1.08
Dividend Gr. 3/5Y	- -	Current Ratio	15.16	EPS Q/Q	-107.83%	SMA20	2.88%	Beta	-0.20	Target Price	15.36
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	11.95%	Rel Volume	0.00	Prev Close	7.10
Employees	28	LT Debt/Eq	0.00	Earnings	Mar 05 BMO	SMA200	113.18%	Avg Volume	601.59K	Price	7.10
IPO	Aug 10, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-31.78% -	Trades		Volume	0	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-24-26	Initiated	B. Riley Securities	Buy	$26
Mar-18-26	Initiated	Truist	Buy	$17
Mar-11-26	Initiated	Raymond James	Strong Buy	$25
Mar-05-26	Initiated	Wedbush	Outperform	$12
Feb-13-26	Initiated	Piper Sandler	Overweight	$23
Oct-16-25	Initiated	William Blair	Outperform
Oct-13-25	Initiated	H.C. Wainwright	Buy	$9
Aug-15-25	Initiated	Robert W. Baird	Outperform	$9
Jun-06-25	Initiated	Oppenheimer	Outperform	$10
May-22-25	Initiated	BTIG Research	Buy	$7
Dec-02-24	Initiated	Leerink Partners	Outperform	$10

Show Previous Ratings

Apr-08-26 07:00AM	Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026 (GlobeNewswire)
Apr-07-26 07:00AM	Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy (GlobeNewswire)
Mar-05-26 07:00AM	Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Feb-26-26 02:11AM	Climb Bio Highlights 2025 Data Catalysts, CD19 and APRIL Programs at Oppenheimer Conference (MarketBeat)
Feb-13-26 03:07AM	Climb Bio Teases 5 Data Readouts in 2026, Highlights CD19 and APRIL Sweeper Programs at Summit (MarketBeat) +7.59%
07:00AM	Loading…
Feb-05-26 07:00AM	Climb Bio to Present at Upcoming Investor Conferences (GlobeNewswire) -7.92%
Jan-08-26 07:00AM	Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 (GlobeNewswire) +9.05%
Dec-31-25 11:13AM	H.C. Wainwright Forecasts 2026 Data Readouts for Climb Bio's (CLYM) Budoprutug Across Clinical Tracks (Insider Monkey)
Nov-25-25 07:00AM	Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-06-25 07:01AM	Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-03-25 07:00AM	Climb Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-31-25 05:42AM	William Blair Initiates Coverage of Climb Bio (CLYM) with Outperform Rating on Autoimmune Drug Potential (Insider Monkey)
Oct-21-25 07:00AM	Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy (GlobeNewswire)
Oct-17-25 07:00AM	Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 (GlobeNewswire)
Oct-01-25 07:00AM	Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer (GlobeNewswire)
07:00AM	Loading…
Sep-29-25 07:00AM	Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN (GlobeNewswire) -6.57%
Sep-11-25 09:40AM	Is Climb Bio, Inc. (CLYM) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-04-25 07:00AM	Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025 (GlobeNewswire)
Sep-03-25 09:55AM	Climb Bio, Inc. (CLYM)'s Technical Outlook is Bright After Key Golden Cross (Zacks) +9.42%
Aug-25-25 02:41PM	UPDATE - Climb Bio to Present at Upcoming September 2025 Investor Conferences (GlobeNewswire)
07:00AM	Climb Bio to Present at Upcoming September 2025 Investor Conferences (GlobeNewswire)
Aug-20-25 09:40AM	Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year? (Zacks) +11.39%
Aug-12-25 07:00AM	Climb Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-03-25 06:25AM	Oppenheimer Predicts Up to 590% Rally for These 2 Strong Buy Stocks (TipRanks)
Jun-18-25 07:00AM	Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer (GlobeNewswire)
May-19-25 04:34PM	Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-14-25 07:00AM	Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire) -7.87%
May-08-25 05:40PM	Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX, ACB (PR Newswire)
Apr-10-25 01:08PM	Exec Edge Launches Research Coverage with Initiation Notes on FLD, CLYM, STKS, REX (Exec Edge)
Apr-01-25 07:00AM	Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors (GlobeNewswire)
07:00AM	Loading…
Mar-27-25 07:00AM	Climb Bio to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-25 04:38PM	Climb Bio Fueled Up with Cash, Poised for More Milestones in 25 Quarterly Update Report (Exec Edge)
Mar-25-25 04:05PM	Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-20-25 02:07PM	Climb Bio: Meet The Newest Star in Autoimmune Disease Treatment Initiation Report (Exec Edge) -5.19%
Feb-25-25 07:00AM	Climb Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-24-25 07:00AM	Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer (GlobeNewswire)
Feb-04-25 07:00AM	Climb Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) -6.03%
Jan-09-25 07:00AM	Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy (GlobeNewswire)
Dec-19-24 07:00AM	Climb Bio to be Added to the Nasdaq Biotechnology Index (GlobeNewswire)
Nov-12-24 04:05PM	Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights (GlobeNewswire) -6.40% -7.11%
Nov-11-24 07:00AM	Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board (GlobeNewswire) +7.12%
Oct-31-24 07:00AM	Climb Bio to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-15-24 07:00AM	Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event (GlobeNewswire) -6.25%
Oct-11-24 12:30PM	Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024 (GlobeNewswire) +5.45%
Oct-04-24 07:00AM	Climb Bio to Present at William Blair's Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19 (GlobeNewswire)
Oct-03-24 10:00AM	Climb Bio to Host Virtual Investor Event on October 15, 2024 (GlobeNewswire)
Oct-02-24 07:04PM	Eliem Therapeutics Changes Name to Climb Bio (Exec Edge)
09:00AM	Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc. (GlobeNewswire)
Sep-11-24 07:00AM	Eliem Therapeutics to Participate at the Stifel 2024 Virtual Immunology and Inflammation Summit (GlobeNewswire)
Aug-26-24 07:00AM	Eliem Therapeutics Announces Additions to its Leadership Team (GlobeNewswire)
Aug-14-24 06:05AM	Eliem Therapeutics Reports Second Quarter Financial Results (GlobeNewswire)
Jul-24-24 12:11AM	Insider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells Shares (GuruFocus.com)
Jul-19-24 03:00PM	Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ... (GuruFocus.com) +7.83%
Jul-18-24 01:01AM	EVP, R&D AND CSO Valerie Morisset Sells 50,000 Shares of Eliem Therapeutics Inc (ELYM) (GuruFocus.com)
Jul-17-24 12:42AM	Insider Sale at Eliem Therapeutics Inc (ELYM): EVP, R&D AND CSO Valerie Morisset Sells ... (GuruFocus.com)
Jul-12-24 01:46AM	Insider Sale at Eliem Therapeutics Inc: EVP, R&D AND CSO Valerie Morisset Sells 105,931 Shares (GuruFocus.com)
Jun-28-24 07:00AM	Eliem Therapeutics Announces its Addition to the Russell 2000 and Russell 3000 Indexes (GlobeNewswire) -5.58%
Jun-27-24 04:01PM	Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement (GlobeNewswire)
May-15-24 01:53PM	ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q1 2024 (InvestorPlace)
Apr-11-24 02:42PM	Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal (Benzinga) +71.54%
07:00AM	Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement (GlobeNewswire)
Apr-05-24 06:53AM	ELYM Stock Earnings: Eliem Therapeutics Reported Results for Q4 2023 (InvestorPlace) -6.81%
Jul-21-23 07:17AM	Eliem (ELYM) to Explore Strategic Options, Stock Rises 6% (Zacks) -8.39%
Jul-20-23 06:45AM	Eliem Therapeutics Announces Plans to Explore Strategic Alternatives (GlobeNewswire) +6.43%
May-11-23 04:10PM	Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights (GlobeNewswire) -10.22%
Apr-21-23 12:00PM	We're Hopeful That Eliem Therapeutics (NASDAQ:ELYM) Will Use Its Cash Wisely (Simply Wall St.)
10:39AM	Top 10 Stocks Activist Investors Are Targeting (Insider Monkey)
Mar-06-23 04:10PM	Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights (GlobeNewswire)
Feb-23-23 12:38AM	Eliem Therapeutics slashing staff amid leadership shakeup (American City Business Journals) +24.35%
Feb-10-23 09:31AM	Eliem Pauses Development On Depression Drug, Lays Off 55% Workforce (Benzinga)
Feb-09-23 04:01PM	Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition (GlobeNewswire)
Nov-30-22 07:00AM	Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference (GlobeNewswire) -5.19%
Nov-14-22 06:10AM	Eliem Therapeutics Reports Third Quarter Financial and Business Highlights (GlobeNewswire)
Nov-12-22 08:47AM	Is Eliem Therapeutics (NASDAQ:ELYM) In A Good Position To Invest In Growth? (Simply Wall St.)
Nov-08-22 07:00AM	Eliem Therapeutics to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Oct-05-22 11:20AM	Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study (Benzinga)
07:00AM	Eliem Therapeutics Provides Update on Pipeline Progress (GlobeNewswire)
Aug-15-22 06:10AM	Eliem Therapeutics Reports Second Quarter Financial and Business Highlights (GlobeNewswire)
Aug-02-22 09:33AM	Eliem's stock slides 20% after saying it will discontinue development of pain treatment (MarketWatch) -10.53%
07:58AM	Eliem Therapeutics Shares Fall On Lower Back Pain Trial Setback (Benzinga)
07:00AM	Eliem Therapeutics Provides ETX-810 Program Update (GlobeNewswire)
Jul-18-22 09:20AM	Eliem Announces Updated Development Plans For Its Delayed Depression Candidate (Benzinga)
07:00AM	Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder (GlobeNewswire)
Jul-07-22 07:00AM	Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022 (GlobeNewswire) +5.92%
Jun-27-22 04:01PM	Eliem Therapeutics Announces Last Patient Completed Dosing in Phase 2a Study of ETX-810 in Patients with Lumbosacral Radicular Pain (LSRP) (GlobeNewswire) +6.30% -6.19%
May-16-22 06:10AM	Eliem Therapeutics Reports First Quarter Financial and Business Highlights (GlobeNewswire) -23.41%
May-10-22 10:45AM	Reata (RETA) Q1 Earnings Top, Omaveloxolone MAA Likely in Q4 (Zacks)
May-09-22 09:55AM	Eliem Therapeutics, Inc. (ELYM) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Apr-25-22 07:00AM	Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs (GlobeNewswire) -55.76%
Apr-05-22 07:00AM	Eliem Therapeutics Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs (GlobeNewswire)
Mar-21-22 07:00AM	Eliem Therapeutics to Present at Stifels 2022 CNS Days (GlobeNewswire)
Mar-07-22 04:10PM	Eliem Therapeutics Reports Fourth Quarter and Year-End Financial and Business Highlights (GlobeNewswire)
Feb-11-22 07:00AM	Eliem Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference (GlobeNewswire) -11.17%
Feb-07-22 07:00AM	Eliem Therapeutics Host Virtual Investor Event Featuring Opinion Leaders in Chronic Pain Research on February 16, 2022 (GlobeNewswire)
Jan-18-22 07:00AM	Eliem Therapeutics Provides Program Updates and an Overview of Expected Near-Term Milestones (GlobeNewswire)
Nov-25-21 07:35AM	15 Pharmaceutical Stocks to Buy According to Peter Kolchinskys RA Capital (Insider Monkey)
Nov-08-21 04:01PM	Eliem Therapeutics Reports Third Quarter Financial and Business Highlights (GlobeNewswire) -10.19% +6.33%
Nov-04-21 07:00AM	Eliem Therapeutics to Participate at Four Upcoming Investor Conferences (GlobeNewswire)
Oct-04-21 10:54AM	Buy These 3 New Stocks Before They Jump Over 60%, Say Analysts (TipRanks)
Sep-13-21 04:10PM	Eliem Therapeutics Reports Second Quarter Financial Results (GlobeNewswire) -12.27%

Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thomas Stephen Basil	Director	Feb 25 '26	Sale	7.00	33,687	235,964	170,970	Feb 27 04:05 PM
Thomas Stephen Basil	Director	Feb 26 '26	Sale	7.01	16,313	114,289	154,657	Feb 27 04:05 PM
STEPHEN THOMAS	Director	Feb 25 '26	Proposed Sale	6.36	50,000	318,000		Feb 25 04:26 PM
Thomas Stephen Basil	Director	Feb 12 '26	Sale	5.23	90,000	470,988	214,657	Feb 17 04:05 PM
Thomas Stephen Basil	Director	Feb 13 '26	Sale	5.81	10,000	58,141	204,657	Feb 17 04:05 PM
STEPHEN THOMAS	Director	Feb 12 '26	Proposed Sale	5.56	100,000	556,000		Feb 12 04:28 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Jan 05 '26	Buy	3.50	7,111	24,888	3,403,429	Jan 07 04:55 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Dec 11 '25	Buy	2.18	213,099	464,556	3,294,856	Dec 15 07:55 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Dec 12 '25	Buy	2.86	101,462	290,181	3,396,318	Dec 15 07:55 PM
Brennan Aoife	President and CEO	Jun 30 '25	Sale	1.22	20,618	25,154	48,132	Jul 01 04:37 PM
Pimblett Emily	SVP, Finance & CAO	Jun 20 '25	Sale	1.24	1,242	1,540	18,888	Jun 20 04:20 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLYM

Climb Bio Inc

Upgrade your Finviz experience